• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

    6/20/24 9:13:29 AM ET
    $BFH
    $IRTC
    $OCUL
    $SWKS
    Real Estate
    Real Estate
    Medical/Dental Instruments
    Health Care
    Get the next $BFH alert in real time by email

    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

    • Wolfe Research analyst Mike Polark upgraded the rating for iRhythm Technologies, Inc. (NASDAQ:IRTC) from Peer Perform to Outperform and announced a price target of $115. iRhythm Technologies shares gained 2.5% to close at $98.16 on Wednesday. See how other analysts view this stock.
    • Evercore ISI Group analyst John Pancari upgraded Bread Financial Holdings, Inc. (NYSE:BFH) from Underperform to In-Line and boosted the price target from $42 to $45. Bread Finl shares gained 0.5% to close at $40.84 on Tuesday. See how other analysts view this stock.
    • TD Cowen analyst Tara Bancroft upgraded the rating for Ocular Therapeutix, Inc. (NASDAQ:OCUL) from Hold to Buy, while raising the price target from $7 to $11. Ocular Therapeutix shares fell 0.2% to settle at $5.49 on Tuesday. See how other analysts view this stock. See how other analysts view this stock.
    • B of A Securities analyst Heather Balsky upgraded the rating for TransUnion (NYSE:TRU) from Neutral to Buy and announced a price target of $92. TransUnion shares slipped 0.01% to close at $71.31 on Tuesday. See how other analysts view this stock.
    • B. Riley Securities analyst Craig Ellis upgraded Skyworks Solutions, Inc. (NASDAQ:SWKS) from Neutral to Buy, while increasing the price target from $96 to $130. Skyworks Solutions shares rose 0.2% to settle at $106.46 on Tuesday. See how other analysts view this stock.

    Check This Out: Sacks Parente Golf And 2 Other Stocks Under $1 Insiders Are Buying

    Get the next $BFH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BFH
    $IRTC
    $OCUL
    $SWKS

    CompanyDatePrice TargetRatingAnalyst
    TransUnion
    $TRU
    2/17/2026$83.00Neutral
    BofA Securities
    Bread Financial Holdings Inc.
    $BFH
    2/5/2026$90.00In-line → Outperform
    Evercore ISI
    Skyworks Solutions Inc.
    $SWKS
    2/4/2026$85.00 → $75.00Buy
    Craig Hallum
    Skyworks Solutions Inc.
    $SWKS
    1/15/2026$65.00Sector Perform
    RBC Capital Mkts
    Bread Financial Holdings Inc.
    $BFH
    1/8/2026$92.00Buy
    UBS
    iRhythm Holdings Inc.
    $IRTC
    1/5/2026$210.00In-line → Outperform
    Evercore ISI
    Bread Financial Holdings Inc.
    $BFH
    12/8/2025Peer Perform
    Wolfe Research
    Bread Financial Holdings Inc.
    $BFH
    12/4/2025$72.00Neutral → Underweight
    Analyst
    More analyst ratings

    $BFH
    $IRTC
    $OCUL
    $SWKS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Notman Donald sold $103,472 worth of shares (11,446 units at $9.04), decreasing direct ownership by 3% to 366,356 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/17/26 8:31:05 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Strategy Officer Nayak Sanjay sold $93,546 worth of shares (10,348 units at $9.04), decreasing direct ownership by 3% to 332,412 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/17/26 8:30:26 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Dugel Pravin sold $1,128,933 worth of shares (124,882 units at $9.04), decreasing direct ownership by 4% to 3,033,078 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/17/26 8:29:16 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFH
    $IRTC
    $OCUL
    $SWKS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities resumed coverage on TransUnion with a new price target

    BofA Securities resumed coverage of TransUnion with a rating of Neutral and set a new price target of $83.00

    2/17/26 7:29:31 AM ET
    $TRU
    Finance: Consumer Services
    Finance

    Bread Financial upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Bread Financial from In-line to Outperform and set a new price target of $90.00

    2/5/26 6:50:02 AM ET
    $BFH
    Real Estate

    Craig Hallum reiterated coverage on Skyworks with a new price target

    Craig Hallum reiterated coverage of Skyworks with a rating of Buy and set a new price target of $75.00 from $85.00 previously

    2/4/26 7:59:43 AM ET
    $SWKS
    Semiconductors
    Technology

    $BFH
    $IRTC
    $OCUL
    $SWKS
    SEC Filings

    View All

    Bread Financial Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - BREAD FINANCIAL HOLDINGS, INC. (0001101215) (Filer)

    2/18/26 7:59:05 AM ET
    $BFH
    Real Estate

    SEC Form SCHEDULE 13G filed by TransUnion

    SCHEDULE 13G - TransUnion (0001552033) (Subject)

    2/13/26 1:54:13 PM ET
    $TRU
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SCHEDULE 13G/A filed by iRhythm Holdings Inc.

    SCHEDULE 13G/A - iRhythm Holdings, Inc. (0001388658) (Subject)

    2/13/26 11:25:53 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $BFH
    $IRTC
    $OCUL
    $SWKS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD

    First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF treatment Superiority primary endpoint met with 74.1% of subjects in the AXPAXLI™ arm maintaining vision at Week 36, a 17.5% risk difference (p=0.0006), compared to aflibercept (2 mg) arm 65.9% of subjects treated with AXPAXLI maintained vision at Week 52, a 21.1% risk difference (p<0.0001), compared to aflibercept (2 mg) arm Rescue-free rates in the AXPAXLI arm were 80.6%, 74.7%, and 68.8% at Weeks 24, 36, and 52 55.9% of subjects treated with AXPAXLI maintained CSFT within 30 μm from baseline at Week 36, a 17.1% risk difference (nominal p=0.0

    2/17/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

    Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET Detailed SOL-1 data to be presented at the 49th Macula Society Annual Meeting BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will host a webcast to review the topline results of the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), on Tuesday, February 17, 2026. Detailed data will be presented at the 49th Macula Society Annual Meeting between

    2/13/26 5:00:00 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransUnion Announces Strong Fourth Quarter and Full-Year 2025 Results

    Exceeded revenue, Adjusted EBITDA and Adjusted Diluted Earnings Per Share guidanceDelivered 13 percent revenue growth, or 12 percent organic constant currencyDrove 19 percent U.S. Financial Services and 16 percent Emerging Verticals revenue growthRepurchased approximately $150 million of shares in fourth quarter for a total of $300 million in 2025Raised quarterly dividend to $0.125 per share, an increase from $0.115, effective fourth quarter of 2025Introducing 2026 financial guidance, we expect to deliver 8 to 9 percent revenue growth CHICAGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- TransUnion (NYSE:TRU) (the "Company") today announced financial results for the quarter and full-year ended Decem

    2/12/26 6:18:13 AM ET
    $TRU
    Finance: Consumer Services
    Finance

    $BFH
    $IRTC
    $OCUL
    $SWKS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fawcett John J. bought $63,459 worth of shares (1,027 units at $61.79), increasing direct ownership by 11% to 10,302 units (SEC Form 4)

    4 - BREAD FINANCIAL HOLDINGS, INC. (0001101215) (Issuer)

    8/1/25 6:28:14 AM ET
    $BFH
    Real Estate

    Director Lindstrom Richard L Md bought $69,600 worth of shares (10,000 units at $6.96), increasing direct ownership by 6% to 172,704 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    5/12/25 8:50:46 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and President Brace Philip G bought $661,300 worth of shares (10,000 units at $66.13) (SEC Form 4)

    4 - SKYWORKS SOLUTIONS, INC. (0000004127) (Issuer)

    2/27/25 6:50:48 PM ET
    $SWKS
    Semiconductors
    Technology

    $BFH
    $IRTC
    $OCUL
    $SWKS
    Financials

    Live finance-specific insights

    View All

    Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD

    First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF treatment Superiority primary endpoint met with 74.1% of subjects in the AXPAXLI™ arm maintaining vision at Week 36, a 17.5% risk difference (p=0.0006), compared to aflibercept (2 mg) arm 65.9% of subjects treated with AXPAXLI maintained vision at Week 52, a 21.1% risk difference (p<0.0001), compared to aflibercept (2 mg) arm Rescue-free rates in the AXPAXLI arm were 80.6%, 74.7%, and 68.8% at Weeks 24, 36, and 52 55.9% of subjects treated with AXPAXLI maintained CSFT within 30 μm from baseline at Week 36, a 17.1% risk difference (nominal p=0.0

    2/17/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransUnion Announces Strong Fourth Quarter and Full-Year 2025 Results

    Exceeded revenue, Adjusted EBITDA and Adjusted Diluted Earnings Per Share guidanceDelivered 13 percent revenue growth, or 12 percent organic constant currencyDrove 19 percent U.S. Financial Services and 16 percent Emerging Verticals revenue growthRepurchased approximately $150 million of shares in fourth quarter for a total of $300 million in 2025Raised quarterly dividend to $0.125 per share, an increase from $0.115, effective fourth quarter of 2025Introducing 2026 financial guidance, we expect to deliver 8 to 9 percent revenue growth CHICAGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- TransUnion (NYSE:TRU) (the "Company") today announced financial results for the quarter and full-year ended Decem

    2/12/26 6:18:13 AM ET
    $TRU
    Finance: Consumer Services
    Finance

    Bread Financial Provides Performance Update for January 2026

    COLUMBUS, Ohio, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Bread Financial® Holdings, Inc. (NYSE:BFH), a tech-forward financial services company that provides simple, personalized payment, lending, and saving solutions to millions of U.S. consumers, provided a performance update. The following tables present the Company's Net principal loss rate and Delinquency rate for the periods indicated:  For themonth endedJanuary 31, 2026 For themonth endedJanuary 31, 2025 (dollars in millions)End-of-period credit card and other loans$18,386  $18,366 Average credit card and other loans$18,531  $18,530 Year-over-year change in average credit card and other loans —%  (2%)Net principal losses$111  $123 Net princ

    2/10/26 7:00:00 AM ET
    $BFH
    Real Estate

    $BFH
    $IRTC
    $OCUL
    $SWKS
    Leadership Updates

    Live Leadership Updates

    View All

    Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer

    Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA® while at Regeneron Most recently served as Chief Marketing Officer, Global Ophthalmology at Merck BEDFORD, Mass., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that David W. Robinson has agreed to join the Company as Global Chief Commercial Officer. The appointment of Mr. Robinson, a proven commercial leader with a history of launching category-defining therapies, strategically positions Ocular for success

    1/21/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransUnion Appoints Francesca Noli Executive Vice President of Global Consumer Solutions

    CHICAGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Francesca Noli joined TransUnion (NYSE:TRU) as Executive Vice President of Global Consumer Solutions today, reporting to Chief Global Solutions Officer, Mohamed Abdelsadek. Noli leads development and market strategy for TransUnion's TruEmpower™ line of solutions, introducing innovations to business customers that accelerate consumer adoption of credit education and identity protection products. She brings over 20 years' experience in product and marketing leadership across financial services, gaming, and enterprise software. Most recently, Noli served as Managing Vice President at Capital One, where she led CreditWise and Money Management in add

    1/5/26 8:00:00 AM ET
    $TRU
    Finance: Consumer Services
    Finance

    TransUnion Appoints Sayan Chakraborty and Charlotte Yarkoni to its Board of Directors

    CHICAGO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- TransUnion (NYSE:TRU) has appointed Sayan Chakraborty and Charlotte Yarkoni to its Board of Directors, effective January 5, 2026. "Sayan and Charlotte have proven track records in fostering product and technology innovation, and generating customer engagement with transformational technology, which will be instrumental as TransUnion continues to evolve our global suite of platforms and products," said Pamela Joseph, Chairperson of the Board. "We're proud to welcome these two visionary leaders to TransUnion's Board." Chakraborty, 58, most recently served as President of Workday, responsible for Product and Technology from 2024 – 2025 and Co-Presi

    12/23/25 6:20:26 AM ET
    $TRU
    Finance: Consumer Services
    Finance

    $BFH
    $IRTC
    $OCUL
    $SWKS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

    SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    11/14/24 5:49:38 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bread Financial Holdings Inc.

    SC 13G/A - BREAD FINANCIAL HOLDINGS, INC. (0001101215) (Subject)

    11/14/24 4:26:27 PM ET
    $BFH
    Real Estate

    SEC Form SC 13G filed by Ocular Therapeutix Inc.

    SC 13G - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    11/14/24 9:37:26 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care